Alnylam Pharmaceuticals Inc. won’t get another chance at its patent infringement suit against Moderna Inc. over its mRNA Covid-19 vaccine, a federal appeals court ruled Wednesday.

H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his ...

Alnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic ...

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $38,973.12 today based on ...

Biogen Inc. is teaming up with a new startup launched by Alnylam Pharmaceuticals’ founding CEO John Maraganore.

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 7.7% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

CAMBRIDGE, Mass., May 28, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman ...

The US regulator’s decision was supported by results from the phase 3 HELIOS-B trial, in which Alnylam’s drug reduced the ...